Monday, November 16, 2026

CMS RELEASES "CRUSH" ANTI FRAUD RULE: ZIPPO RE LABS

CMS has released a proposed version of its new anti fraud CRUSH rules.  While the roll-out seemed to be "half DME and half lab industry," the proposed rule hardly mentions the word "laboratory."

Press:

https://www.cms.gov/newsroom/press-releases/cms-crush-proposed-rule-aims-reap-nearly-90-billion-taxpayers-savings-targeting-fraud-across

FAQ:

https://www.cms.gov/newsroom/fact-sheets/comprehensive-regulations-uncover-suspicious-healthcare-crush-proposed-rule-cms-6098-p

Proposal:

https://public-inspection.federalregister.gov/2026-23461.pdf


CMS Releases CRUSH: 545 Pages on Fraud, and Labs Barely Appear

On November 16, 2026, CMS released the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule, CMS-6098-P. The agency says it would save nearly $90 billion over ten years across Medicare, Medicaid/CHIP and the ACA Marketplace. It is a standalone, discretionary program integrity rule rather than an annual payment rule. CMS says it intends to issue a rule like this every year from now on. The Federal Register publishes it November 19, and comments are due January 19, 2027.

The press release goes heavily after DME, hospice and Marketplace brokers. Administrator Oz's quote mentions fake canes and wheelchairs, healthy seniors enrolled in hospice, and consumers signed up for Marketplace plans without their consent. The largest single dollar item is Medicare Advantage RADV reform. CMS would codify no fee-for-service adjuster and extrapolation starting with payment year 2018 audits, which it estimates at about $9 billion per payment year. Other items include mandatory fraud reporting by MA and Part D plans, a new Medicaid audit structure for eligibility, a 60-day overpayment rule for Medicaid fee-for-service, and tighter rules for Marketplace agents and brokers.

Where are the labs?

Much of the recent fraud debate in diagnostics has been about laboratory billing. Readers in that sector might have expected a large lab section. There isn't one. Explicit references to laboratories are sparse and largely incidental. The word "laboratory," for example, appears 3 times.

  • once in a Medicaid list of "disclosing entities" (p. 213)
  • once in a regulatory subject index
  • once as a reassurance that a medical building housing "two laboratories" next to other practices is not, in itself, a sign of fraud (p. 199)

Genetic testing comes up only once. It appears in a DOJ case summary in the DMEPOS section (p. 184): a Texas defendant sentenced in March 2026 for a $61.5 million scheme. An offshore call center sold Medicare beneficiaries braces, foot baths and genetic tests they did not need. There is no lab provision, no CLIA hook, and nothing about MolDX, PLA codes or test-specific edits.

  • The rule does contain several broad enrollment changes that apply to every provider and supplier type, including independent labs.
  • For lab compliance teams, those are the parts to read.

Cross-cutting enrollment provisions labs should note

One 30-day clock for all changes. Most providers and suppliers now have 30 days to report critical changes (ownership, practice location, adverse actions) and up to 90 days for everything else. CRUSH would make every change reportable within 30 days, regardless of provider type (pp. 196–197). IDTFs are named specifically in § 410.33(g)(2). CMS says it does not plan to revoke every late filer, but the shorter clock applies to everyone.

Removing the factors CMS must weigh before denying or revoking. This may be the most consequential change for any supplier. Many of the current denial and revocation grounds in §§ 424.530 and 424.535 list factors CMS must consider, such as how late the data was, how material it was, and whether the provider has any history of adverse actions. CMS argues that most aberrant billing comes from providers with clean histories, so those factors work in their favor. It proposes to "remove all factors" from these grounds (pp. 192–196). Revocation for a pattern of abusive billing has historically been an important tool against problem labs. Labs that are suppliers in good standing would also lose some of the structure that currently constrains CMS's discretion.

Owners whose identity can't be verified, or who pose "undue risk." New §§ 424.530(a)(25) and 424.535(a)(30) would let CMS deny or revoke enrollment when an owner, managing employee, officer or director cannot be identified or located. They would also apply when CMS decides that person poses an undue risk of fraud, waste or abuse (pp. 205–207). Foreign ownership is the stated concern. CMS can also ask for passports, driver's licenses or birth certificates when other verification fails. Lab schemes that used straw owners would fall within this provision, though "undue risk" is not defined.

Denial or revocation tied to ownership changes, for any provider type. Proposed § 424.536 would let CMS deny or revoke any provider involved in a change of majority ownership, meaning a buyer acquiring more than 50%. That applies if any party failed to meet enrollment requirements or if CMS finds undue risk. It applies regardless of provider type, timing, or whether the business changes its name (pp. 200–203). Unlike the 36-month rules for hospices, HHAs and DMEPOS, this one is not limited to particular provider types. Lab acquisitions, including roll-ups of small regional labs, would be covered.

"Misuse of billing number" becomes "improper activity." Section 424.535(a)(7) currently covers selling or lending a billing number. It would be broadened to cover any improper activity involving enrollment, identifiers or EFT arrangements. CMS's example is a provider that obtains Medicare Beneficiary Identifiers and sells them (p. 205). Lab fraud investigators will recognize the beneficiary-ID harvesting it describes. The rule says the provision would be used "only in exceptional circumstances," and "improper" would take its plain-language meaning.

Shared offices and geographic clusters. Grounds first proposed in the July 2026 CY 2027 HH PPS rule would now work as both denial and revocation bases. They cover sharing an office or suite with a revoked provider, and being located in a small area with an excessive number of providers (pp. 197–199). The examples are home health agencies and hospices, but the text is not limited to those types. This is the passage where CMS notes that two labs in a medical complex are not suspicious in themselves.

Medicare Advantage billers must enroll in Original Medicare. Every eligible provider billing MA would have to be enrolled in Original Medicare in approved status. This would take effect at the start of the plan year beginning two years after the final rule. Most labs are already enrolled, but an MA-only biller would need to go through full FFS screening.

Medicaid alignment. Medicaid and CHIP would gain termination grounds that mirror Medicare's, including abusive ordering, certifying or referring. This is the closest the rule comes to describing lab overutilization: CMS warns that "a physician ordering tests that patients do not require" puts patients at risk and wastes program funds (p. 230). Labs billing Medicaid fee-for-service would also come under the new 60-day rule for reporting and returning overpayments, along with expanded state reporting and NPI requirements.

What isn't there

Two gaps stand out for diagnostics. First, new § 424.535(a)(29) would let CMS revoke a physician who orders even one DMEPOS item that is not reasonable and necessary, with no prior finding of fraud. CMS limits this explicitly to DMEPOS, saying DME suppliers pose a program integrity threat "higher, perhaps, than any other" supplier type (p. 191). It does not reach physicians who sign telemedicine orders for genetic tests, even though the case CMS cites involved exactly that.

Second, the expanded ban on unsolicited contact covers texts, social media direct messages, email without an opt-out, and door-to-door visits. It remains a DMEPOS supplier standard and does not cover marketers selling lab tests.

The lab industry may have escaped direct attention in this round. CMS has said it plans an annual series of these rules, so labs could be addressed in a later one.

The proposed rule is at public-inspection.federalregister.gov/2026-23461.pdf; the docket is CMS-2026-0826 on regulations.gov.


Page numbers refer to the 545-page public-inspection PDF.